• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

真性红细胞增多症和原发性血小板增多症患者体外血块溶解减少,且释放出更具活性的血小板纤溶酶原激活物抑制因子-1。

Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia.

作者信息

Pósán E, Ujj G, Kiss A, Telek B, Rák K, Udvardy M

机构信息

2nd Department of Medicine, University Medical School, Debrecen, Hungary.

出版信息

Thromb Res. 1998 Apr 15;90(2):51-6. doi: 10.1016/s0049-3848(98)00005-x.

DOI:10.1016/s0049-3848(98)00005-x
PMID:9684757
Abstract

Because platelets interact with fibrinolysis in a complex manner, it can be expected that with abnormal platelet numbers and quality this interference can be even more profound. The aim of this work was to study the lysis-resistance of platelet-rich clots in diseases with high platelet counts: polycythemia vera (PV), essential thrombocythemia (ET) and to make comparison with polyglobulia (PG). Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) were analyzed by an in vitro clot lysis test. Plasminogen activator inhibitor-1 (PAI-1) activity was measured in plasma and in the supernatants of the washed and gel-filtered platelets after activation by thrombin. The lysis showed decreased speed of PPP-clots in PV and ET. This phenomenon was even more marked in PRP-clots from PV and ET, but further increased lysis resistance after retraction was not observed in PV and ET, most likely due to abnormal platelet functions. Our results suggest that the fibrinolytic activity is reduced in PV and ET, and may play a role both in the increased aptitude for venous thrombosis and in the arterial complications. These are partly caused by higher plasmatic PAI-1 activity as well as by more active platelet PAI-1. The PAI-1 activity was significantly higher in the supernatants of the washed and gel-filtered platelets of PV after activation by thrombin compared with controls. Other factors might have influenced the reduced fibrinolysis.

摘要

由于血小板以复杂的方式与纤维蛋白溶解相互作用,可以预期,在血小板数量和质量异常的情况下,这种干扰可能会更加严重。这项工作的目的是研究血小板计数高的疾病(真性红细胞增多症(PV)、原发性血小板增多症(ET))中富含血小板凝块的溶解抗性,并与红细胞增多症(PG)进行比较。通过体外凝块溶解试验分析富含血小板血浆(PRP)和贫血小板血浆(PPP)。在血浆以及经凝血酶激活后的洗涤和凝胶过滤血小板的上清液中测量纤溶酶原激活物抑制剂-1(PAI-1)活性。结果显示,PV和ET中PPP凝块的溶解速度降低。这种现象在PV和ET的PRP凝块中更为明显,但在PV和ET中未观察到回缩后溶解抗性的进一步增加,这很可能是由于血小板功能异常。我们的结果表明,PV和ET中的纤维蛋白溶解活性降低,可能在静脉血栓形成倾向增加和动脉并发症中都起作用。这些部分是由较高的血浆PAI-1活性以及更活跃的血小板PAI-1引起的。与对照组相比,经凝血酶激活后,PV洗涤和凝胶过滤血小板的上清液中PAI-1活性显著更高。其他因素可能也影响了纤维蛋白溶解的降低。

相似文献

1
Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia.真性红细胞增多症和原发性血小板增多症患者体外血块溶解减少,且释放出更具活性的血小板纤溶酶原激活物抑制因子-1。
Thromb Res. 1998 Apr 15;90(2):51-6. doi: 10.1016/s0049-3848(98)00005-x.
2
[Fibrinolysis studied by an in vitro clot lysis test in polycythemia vera].[真性红细胞增多症中通过体外凝块溶解试验研究纤溶作用]
Orv Hetil. 1996 Jan 14;137(2):71-4.
3
Altered plasma fibrin clot properties in essential thrombocythemia.原发性血小板增多症患者的血浆纤维蛋白凝块特性改变。
Platelets. 2016;27(2):110-6. doi: 10.3109/09537104.2015.1042967. Epub 2015 May 19.
4
Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets.血小板释放1型纤溶酶原激活物抑制剂对溶栓作用的减弱。
Thromb Res. 1993 Dec 1;72(5):413-21. doi: 10.1016/0049-3848(93)90241-f.
5
High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis.真性红细胞增多症和原发性血小板增多症患者血浆中纤溶酶原激活物抑制剂1(PAI-1)水平升高与血栓形成有关。
Thromb Res. 1994 Sep 1;75(5):513-20. doi: 10.1016/0049-3848(94)90226-7.
6
Platelet-related fibrinolysis resistance in patients suffering from PV. Impact of clot retraction and isovolemic erythrocytapheresis.真性红细胞增多症患者血小板相关的纤溶抵抗。凝块回缩和等容红细胞单采术的影响。
Thromb Res. 2014 Jul;134(1):192-8. doi: 10.1016/j.thromres.2014.04.025. Epub 2014 May 2.
7
The potential role of platelet PAl-1 in t-PA mediated clot lysis of platelet rich plasma.血小板纤溶酶原激活物抑制剂-1在组织型纤溶酶原激活剂介导的富血小板血浆凝块溶解中的潜在作用。
Thromb Res. 1993 Aug 15;71(4):289-300. doi: 10.1016/0049-3848(93)90198-w.
8
Fibrinolytic imbalance in essential thrombocythemia: role of platelets.原发性血小板增多症中的纤溶失衡:血小板的作用
Haemostasis. 1993;23(1):38-44. doi: 10.1159/000216850.
9
Altered lysis resistance of platelet-rich clots in patients with insulin-dependent diabetes mellitus.
Thromb Res. 1995 Jul 1;79(1):57-63. doi: 10.1016/0049-3848(95)00090-e.
10
Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera.校准的自动化血栓生成仪检测到血小板诱导的凝血酶生成在原发性血小板增多症和红细胞增多症患者中增加。
Am J Hematol. 2011 Apr;86(4):337-42. doi: 10.1002/ajh.21974.

引用本文的文献

1
JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.JAK2V617F 等位基因变异频率、非驱动突变、单核苷酸变异与原发性骨髓纤维化结局。
J Cancer Res Clin Oncol. 2023 Jul;149(8):4789-4803. doi: 10.1007/s00432-022-04327-0. Epub 2022 Oct 15.
2
Biophysical Mechanisms Mediating Fibrin Fiber Lysis.介导纤维蛋白纤维溶解的生物物理机制。
Biomed Res Int. 2017;2017:2748340. doi: 10.1155/2017/2748340. Epub 2017 May 28.
3
JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells.
JAK2-V617F诱导的丝裂原活化蛋白激酶(MAPK)活性受磷脂酰肌醇-3激酶(PI3K)调控,并与PI3K协同作用于JAK2-V617F阳性细胞的增殖。
JAKSTAT. 2013 Jul 1;2(3):e24574. doi: 10.4161/jkst.24574. Epub 2013 Apr 8.
4
Prevalence of venous thromboembolism in patients with secondary polycythemia.继发性红细胞增多症患者静脉血栓栓塞症的患病率。
Clin Appl Thromb Hemost. 2013 Jul-Aug;19(4):363-6. doi: 10.1177/1076029612460425. Epub 2012 Sep 23.
5
Clinical implications of elevated PAI-1 revisited: multiple arterial thrombosis in a patient with essential thrombocythemia and elevated plasminogen activator inhibitor-1 (PAI-1) levels: a case report and review of the literature.PAI-1升高的临床意义再探讨:一例原发性血小板增多症且纤溶酶原激活物抑制剂-1(PAI-1)水平升高患者的多发性动脉血栓形成:病例报告及文献复习
J Thromb Thrombolysis. 1999 Aug;8(2):105-12. doi: 10.1023/a:1008907001042.